IDiyas

For the Inventor, By the Inventor

Omiya, Japan

Katsuo Hatayama

USPTO Granted Patents = 38

 

Average Co-Inventor Count = 5.1

ph-index = 10

Forward Citations = 295(Granted Patents)


Location History:

  • Omiya, JA (1978)
  • Ohmiya, JP (1985 - 1994)
  • Omiya, JP (1984 - 1995)
  • Saitama, JP (1994 - 1996)
  • Tokyo, JP (1995 - 1998)

Company Filing History:

goldMedal38 out of 314 
 
Taisho Pharmaceutical Co., Ltd.
 patents
silverMedal1 out of 114 
 
Chinese Academy of Medical Sciences
 patents
where one patent can have more than one assignee

Years Active: 1978-1998

where 'Filed Patents' based on already Granted Patents

38 patents (USPTO):
1. 5753673 - Quinolinecarboxylic acid derivatives (1998-05-19),
2. 5733917 - Heterocyclic compound (1998-03-31),
3. 5712263 - Steroid derivatives (1998-01-27),
4. 5672712 - Thiazoline derivatives (1997-09-30),
5. 5631355 - 5-O-desosaminylerythronolide a derivatives (1997-05-20),
6. 5631354 - 5-O-desosaminylerythronolide derivatives (1997-05-20),
7. 5602239 - 5-O-desosaminylerythronolide derivatives (1997-02-11),
8. 5597921 - Indolo[2,3-b]quinoxaline derivatives (1997-01-28),
9. 5591837 - 5-O-desosaminylerythronolide a derivative (1997-01-07),
10. 5571820 - Heterocyclic compound (1996-11-05),
11. 5523399 - 5-O-desosaminylerythronolide derivatives (1996-06-04),
12. 5521311 - 5-aminoacetylaminosulfonanilide compounds (1996-05-28),
13. 5502202 - Aminoalkylthiazole derivative (1996-03-26),
14. 5496829 - Use of 2-nitroxyethyl (+)apovincaminate (1996-03-05),
15. 5495046 - Alkoxyphenylalkylamine derivatives (1996-02-27),

Title: The Innovations of Katsuo Hatayama: A Pioneer in Gastrointestinal Research

Introduction

Katsuo Hatayama, based in Omiya, Japan, has made significant contributions to the field of gastrointestinal medicine through his innovative research and prolific patent portfolio. With a remarkable total of 38 patents, he stands out as an influential inventor in his domain.

Latest Patents

Among his latest innovations, Hatayama's patents include Quinolinecarboxylic acid derivatives and a heterocyclic compound known as Endo-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl) 1-isopropyl-2(1H)-quinolone-3-carboxylate. This compound represents a breakthrough in activating serotonin 4 receptors, leading to advancements in the treatment of various gastrointestinal conditions. His work has shown promise in alleviating issues such as heartburn, anorexia, bowel pain, and abdominal distension, which can arise from chronic gastritis or postoperative gastroparesis. Furthermore, it offers potential solutions for gastro-esophageal reflux, intestinal pseudo-obstruction, and constipation.

Career Highlights

Throughout his career, Katsuo Hatayama has been associated with prestigious organizations such as Taisho Pharmaceutical Co., Ltd. and the Institute of Materia Medica of the Chinese Academy of Medical Sciences. His expertise and dedication to research have positioned him as a leading figure in the pharmaceutical industry, particularly in the development of novel treatments for gastrointestinal disorders.

Collaborations

Hatayama has collaborated with prominent figures in the field, including Yutaka Kawashima and Sadakazu Yokomori. These partnerships have enhanced his research capabilities and contributed to the advancement of innovative solutions in gastrointestinal health.

Conclusion

Katsuo Hatayama's work exemplifies the spirit of innovation and dedication to improving human health. His extensive patent portfolio and collaborative efforts with esteemed colleagues in the industry underscore his role as a pioneer in developing effective treatments for gastrointestinal conditions, making him a noteworthy inventor in the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…